Related Experiment Video
Updated: Aug 18, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular
Ganna V Kalayda1, Bart A J Jansen, Peter Wielaard
1Gorlaeus Laboratories, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands.
Abstract:
The biological activity of N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones (aminoalkyl is 2-aminoethyl, 3-aminoprop-1-yl and 4-aminobut-1-yl) and their dinuclear platinum complexes has been evaluated in the U2-OS human osteosarcoma cell line and its cisplatin-resistant U2-OS/Pt subline. All the compounds have been found to exhibit high cytotoxicity in the sensitive cell line, and to overcome cisplatin resistance in U2-OS/Pt cells. Cellular processing of N,N'-bis(2-aminoethyl)-1,4-diaminoanthraquinone and the respective dinuclear platinum complex in the sensitive and resistant U2-OS cells has been studied over time using digital fluorescence microscopy. Cellular processing of the compounds has been found to be similar in sensitive and resistant U2-OS cells, which is in agreement with the lack of cross-resistance in the U2-OS/Pt cell line. Both the platinum complex and the free ligand quickly enter the cell and accumulate in the nucleus. The platinum complex is excreted from the cell via the Golgi apparatus, while the weakly basic anthraquinone ligand accumulates in the Golgi complex, where it is taken up by lysosomes and then transported to the cell surface. The cellular distribution of the fluorescent anthraquinones and their dinuclear platinum complexes in the sensitive/resistant pair of U2-OS osteosarcoma cell lines is compared with the earlier studied cellular processing in the sensitive/resistant pair of A2780 ovarian carcinoma cell lines. In the A2780cisR cell line, the platinum complexes (and not the free ligands) are sequestered in lysosomes, which is not the case in A2780 sensitive cells. The differences in cellular distribution of the compounds in these two sensitive/resistant pairs of cell lines most likely result from different resistance profiles in A2780cisR and U2-OS/Pt cells. Lysosomes of A2780cisR cells are less acidic than lysosomes of A2780 sensitive cells, which is likely to be the cause of a defect in endocytosis. The disruption of normal endocytosis might facilitate sequestration of the platinum complexes in lysosomes, which partly confers the cross-resistance of these complexes with cisplatin in the A2780cisR cell line. In contrast, sequestration in acidic vesicles does not occur in U2-OS/Pt cells that do not exhibit enhanced lysosomal pH and which are likely to have normal endocytosis.
Insights
New platinum complexes and their anthraquinone ligands show high cytotoxicity against osteosarcoma cells and overcome cisplatin resistance. Cellular processing is similar in resistant and sensitive cells, unlike in ovarian cancer lines where lysosomal sequestration confers resistance.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Platinum-based drugs are crucial in cancer chemotherapy but face challenges with drug resistance.
- Anthraquinone derivatives have shown potential biological activities.
- Understanding cellular processing is key to overcoming drug resistance mechanisms.
Purpose of the Study:
- To evaluate the biological activity of novel N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones and their dinuclear platinum complexes.
- To assess the efficacy of these compounds against cisplatin-sensitive and cisplatin-resistant human osteosarcoma cell lines (U2-OS and U2-OS/Pt).
- To investigate and compare the cellular processing and distribution of these compounds in sensitive and resistant cell lines.
Main Methods:
- Cytotoxicity assays were performed on U2-OS and U2-OS/Pt cell lines.
- Digital fluorescence microscopy was used to study the time-dependent cellular processing of selected compounds.
- Cellular distribution was compared between U2-OS/Pt and A2780cisR (ovarian cancer) resistant cell lines.
Main Results:
- All evaluated compounds exhibited high cytotoxicity in U2-OS cells and effectively overcame cisplatin resistance in U2-OS/Pt cells.
- Cellular processing of the anthraquinone ligand and its platinum complex was similar in both sensitive and resistant U2-OS cells.
- Unlike in A2780cisR cells, sequestration in lysosomes was not observed in U2-OS/Pt cells, correlating with normal endocytosis and lack of cross-resistance.
Conclusions:
- The novel N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinone platinum complexes are potent anticancer agents capable of overcoming cisplatin resistance.
- Cellular processing differences, particularly lysosomal sequestration in A2780cisR cells, explain varied resistance profiles compared to U2-OS/Pt cells.
- These findings highlight the potential of these compounds for developing new therapeutic strategies against resistant cancers.
Related Concept Videos
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

